期刊
PATHOLOGY RESEARCH AND PRACTICE
卷 216, 期 8, 页码 -出版社
ELSEVIER GMBH
DOI: 10.1016/j.prp.2020.152963
关键词
Hepatocellular carcinoma; Lidocaine; USP14; PI3K/Akt
类别
资金
- 2018 provincial natural science research project [2018CFC803]
Previous studies have found that Lidocaine (Lido) has marked anti-tumor effects. The purpose of this study was to explore the effect and mechanism of Lido on hepatocellular carcinoma (HCC). Here, the Huh-7 and SMMC-7721 HCC cells were treated with Lido, then the proliferation, migration and invasion of HCC cells were detected by CCK8, wounding healing assay and Transwell assay. Besides, apoptotic proteins (including Caspase3 and Bcl2), epithelial-mesenchymal transition (EMT) associated markers (including E-cadherin and Vimentin), USP14, PI3K/Akt pathway were detected by western blot. Our results revealed that Lido significantly inhibited the proliferation, migration and invasion while aggravate the apoptosis of HCC cells, as well as the expression of USP14 and the activation of PI3K/Akt. Loss-of-function experiments confirmed that USP14 downregulation attenuated the malignant behaviors of HCC cells through repressing PI3K/Akt signaling pathway. Mechanistically, USP14 functioned by deubiquitinating and activating PI3K. In conclusion, Lido inhibits the proliferation and metastasis of HCC cells by targeting USP14 and its downstream PI3K/Akt signaling pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据